Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Aloe extract UP-780 upregulates adiponectin expression, reduces HbA1c

Aug. 12, 2008

Xanodyne reports positive results from two phase III clinical trials of tranexamic acid

Aug. 11, 2008

Hematide phase III program cleared to continue by DMC

Aug. 11, 2008

Oramed reports positive results from phase IIa clinical trial of ORMD-0801 in type 2 diabetes

Aug. 8, 2008

BioSante reacquires Elestrin from Nycomed

Aug. 8, 2008

Mipomersen enters second phase III trial

Aug. 8, 2008

Tolerx initiates phase III DEFEND clinical trial of otelixizumab in type 1 diabetes

Aug. 7, 2008

Generex is granted approval to initiate trial of Generex Oral-lyn in IGT

Aug. 6, 2008

Novartis completes recruitment into phase III study of salmon calcitonin

Aug. 6, 2008

Recent patents report discovery of novel antidiabetic agents

Aug. 6, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...